Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.39 |
| ▸ | FEN1 | P39748 | 3/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822555 | 1.00 | ALOX5AP (0.39) | ALOX5APFEN1CCNCCDK8FDFT1 | |
| SCHEMBL12823442 | 0.93 | ALOX5AP (0.38) | ALOX5APFEN1CCNCCDK8FDFT1 | |
| SCHEMBL12742477 | 0.89 | ALOX5AP (0.42) | ALOX5APFEN1CCNCCDK8FPR2 | |
| SCHEMBL12737388 | 0.89 | ALOX5AP (0.42) | ALOX5APFEN1CCNCCDK8FPR2 | |
| SCHEMBL12742468 | 0.89 | ALOX5AP (0.42) | ALOX5APFEN1OXTRAVPR1AFPR2 | |
| SCHEMBL12737385 | 0.89 | ALOX5AP (0.42) | ALOX5APFEN1OXTRAVPR1AFPR2 | |
| SCHEMBL12823696 | 0.89 | ALOX5AP (0.40) | ALOX5APFEN1CCNCCDK8FPR2 | |
| SCHEMBL12821274 | 0.88 | ALOX5AP (0.35) | ALOX5APFEN1CCNCCDK8FDFT1 | |
| SCHEMBL13586454 | 0.88 | ALOX5AP (0.37) | ALOX5APFEN1OXTRAVPR1AFPR2 | |
| SCHEMBL12821284 | 0.88 | MAPT (0.33) | ALOX5APFEN1CCNCCDK8FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | ALOX5AP 1673/4885FEN1 3340/4885CCNC 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.